Cargando…

Access to Hematopoietic Stem Cell Transplant in Canada for Patients with Acute Myeloid Leukemia

Hematopoietic stem cell transplant is a complicated intervention only offered in specialized centers. Access to transplants may vary based on the location of primary residence, income levels, age, and reported race or ethnicity. Using data from the Canadian Institute of Health (CIH) Discharge abstra...

Descripción completa

Detalles Bibliográficos
Autores principales: Morakinyo, Oluwatobiloba, Bucher, Oliver, Paulson, Kristjan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9332420/
https://www.ncbi.nlm.nih.gov/pubmed/35892981
http://dx.doi.org/10.3390/curroncol29080412
_version_ 1784758642567806976
author Morakinyo, Oluwatobiloba
Bucher, Oliver
Paulson, Kristjan
author_facet Morakinyo, Oluwatobiloba
Bucher, Oliver
Paulson, Kristjan
author_sort Morakinyo, Oluwatobiloba
collection PubMed
description Hematopoietic stem cell transplant is a complicated intervention only offered in specialized centers. Access to transplants may vary based on the location of primary residence, income levels, age, and reported race or ethnicity. Using data from the Canadian Institute of Health (CIH) Discharge abstract database (DAD), all non-Quebec Canadians under the age of 65 with a diagnosis of AML between 2004 and 2015 were included in this study. Descriptive statistics were produced for the variables of interest: time period, age, sex, rurality, transplant status, proportion of visible minorities, proportion identifying as indigenous, and proportion of low-income families. Transplant rates were compared and reported using univariable and multivariable analysis. In multivariable analysis, time period, province of residence, gender, and age were significantly associated with the receipt of an allogeneic hematopoietic stem cell transplant. However, differences in transplant rates observed in indigenous patients, low-income families, and visible minorities were not found to be statistically significant. In non-Quebec Canada, transplant rates vary significantly with province of residence, with the highest rates recorded in Alberta. Contrary to findings previously reported in studies exploring access to transplant in the United States, a low-income level was not associated with lower rates of transplants. This might suggest that Canada’s universal health care insurance program is protective against socioeconomic barriers that impact access to health care services.
format Online
Article
Text
id pubmed-9332420
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93324202022-07-29 Access to Hematopoietic Stem Cell Transplant in Canada for Patients with Acute Myeloid Leukemia Morakinyo, Oluwatobiloba Bucher, Oliver Paulson, Kristjan Curr Oncol Article Hematopoietic stem cell transplant is a complicated intervention only offered in specialized centers. Access to transplants may vary based on the location of primary residence, income levels, age, and reported race or ethnicity. Using data from the Canadian Institute of Health (CIH) Discharge abstract database (DAD), all non-Quebec Canadians under the age of 65 with a diagnosis of AML between 2004 and 2015 were included in this study. Descriptive statistics were produced for the variables of interest: time period, age, sex, rurality, transplant status, proportion of visible minorities, proportion identifying as indigenous, and proportion of low-income families. Transplant rates were compared and reported using univariable and multivariable analysis. In multivariable analysis, time period, province of residence, gender, and age were significantly associated with the receipt of an allogeneic hematopoietic stem cell transplant. However, differences in transplant rates observed in indigenous patients, low-income families, and visible minorities were not found to be statistically significant. In non-Quebec Canada, transplant rates vary significantly with province of residence, with the highest rates recorded in Alberta. Contrary to findings previously reported in studies exploring access to transplant in the United States, a low-income level was not associated with lower rates of transplants. This might suggest that Canada’s universal health care insurance program is protective against socioeconomic barriers that impact access to health care services. MDPI 2022-07-22 /pmc/articles/PMC9332420/ /pubmed/35892981 http://dx.doi.org/10.3390/curroncol29080412 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Morakinyo, Oluwatobiloba
Bucher, Oliver
Paulson, Kristjan
Access to Hematopoietic Stem Cell Transplant in Canada for Patients with Acute Myeloid Leukemia
title Access to Hematopoietic Stem Cell Transplant in Canada for Patients with Acute Myeloid Leukemia
title_full Access to Hematopoietic Stem Cell Transplant in Canada for Patients with Acute Myeloid Leukemia
title_fullStr Access to Hematopoietic Stem Cell Transplant in Canada for Patients with Acute Myeloid Leukemia
title_full_unstemmed Access to Hematopoietic Stem Cell Transplant in Canada for Patients with Acute Myeloid Leukemia
title_short Access to Hematopoietic Stem Cell Transplant in Canada for Patients with Acute Myeloid Leukemia
title_sort access to hematopoietic stem cell transplant in canada for patients with acute myeloid leukemia
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9332420/
https://www.ncbi.nlm.nih.gov/pubmed/35892981
http://dx.doi.org/10.3390/curroncol29080412
work_keys_str_mv AT morakinyooluwatobiloba accesstohematopoieticstemcelltransplantincanadaforpatientswithacutemyeloidleukemia
AT bucheroliver accesstohematopoieticstemcelltransplantincanadaforpatientswithacutemyeloidleukemia
AT paulsonkristjan accesstohematopoieticstemcelltransplantincanadaforpatientswithacutemyeloidleukemia